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ABSTRACT
Introduction We explored the presence of chronic 
complications in subjects with newly diagnosed type 2 
diabetes referred to the Verona Diabetes Clinic. Metabolic 
(insulin secretion and sensitivity) and clinical features 
associated with complications were also investigated.
Research design and methods The comprehensive 
assessment of microvascular and macrovascular 
complications included detailed medical history, resting 
ECG, ultrasonography of carotid and lower limb arteries, 
quantitative neurological evaluation, cardiovascular 
autonomic tests, ophthalmoscopy, kidney function tests. 
Insulin sensitivity and beta- cell function were assessed 
by state- of- the- art techniques (insulin clamp and 
mathematical modeling of glucose/C- peptide curves 
during oral glucose tolerance test).
Results We examined 806 patients (median age years, 
two- thirds males), of whom prior clinical cardiovascular 
disease (CVD) was revealed in 11.2% and preclinical 
CVD in 7.7%. Somatic neuropathy was found in 21.2% 
and cardiovascular autonomic neuropathy in 18.6%. 
Retinopathy was observed in 4.9% (background 4.2%, 
proliferative 0.7%). Chronic kidney disease (estimated 
glomerular filtration rate <60 mL/min/1.73 m2) was 
found in 8.8% and excessive albuminuria in 13.2% 
(microalbuminuria 11.9%, macroalbuminuria 1.3%).
Isolated microvascular disease occurred in 30.8%, isolated 
macrovascular disease in 9.3%, a combination of both in 
9.1%, any complication in 49.2% and no complications in 
50.8%.
Gender, age, body mass index, smoking, hemoglobin A1c 
and/or hypertension were independently associated with 
one or more complications. Insulin resistance and beta- cell 
dysfunction were associated with macrovascular but not 
microvascular disease.
Conclusions Despite a generally earlier diagnosis for an 
increased awareness of the disease, as many as ~50% 
of patients with newly diagnosed type 2 diabetes had 
clinical or preclinical manifestations of microvascular and/
or macrovascular disease. Insulin resistance might play an 
independent role in macrovascular disease.
Trial registration number NCT01526720.
INTRODUCTION
The stages of type 2 diabetes mellitus (T2DM) 
include a period in which the disease is undi-
agnosed. In the 90s, the time elapsing before 
Significance of this study
What is already known about this subject?
 ► Type 2 diabetes mellitus (T2DM) can remain undiag-
nosed for years before being detected.
 ► Unrecognized and untreated hyperglycemia could 
result in organ damage and contribute to classic 
macrovascular and microvascular complications.
What are the new findings?
 ► When carefully searched, chronic complications of 
diabetes are revealed in as many as 50% of patients 
with newly diagnosed T2DM.
 ► Microvascular, mainly neurological, are more preva-
lent than macrovascular complications.
 ► State- of- the- art assessed insulin resistance and 
beta- cell dysfunction are independently associated 
with macrovascular complications.
How might these results change the focus of 
research or clinical practice?
 ► More effective strategies to anticipate T2DM diagno-
sis seem to be warranted.
 ► A more detailed and comprehensive search for or-
gan/system damage should be implemented as 
soon as the diagnosis of T2DM is established.
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diagnosis was estimated to be up to 10 years.1 Hypergly-
cemia can generate functional and structural damages 
which might yield macrovascular and/or microvascular 
complications during this more or less long period of 
undetected disease. In fact, a number of studies reported 
that a sizable proportion of subjects with newly diagnosed 
T2DM already have chronic complications.2–16 Nowadays, 
at least in Western countries, T2DM is probably diagnosed 
at an earlier stage17 and this might have reduced the prev-
alence of complications at time of diagnosis. However, 
an updated information on the prevalence of chronic 
complications when T2DM is first diagnosed is rather 
scant and generally incomplete. Most studies, in fact, 
did not focus on all potential complications and none of 
them carefully evaluated subclinical vascular disease. Yet, 
very few studies have explored the association of compli-
cations with main pathogenic defects of T2DM, that is, 
insulin resistance and beta- cell dysfunction.
The aim of the present study was to assess the preva-
lence and associated clinical and metabolic features 
of all traditional chronic complications of T2DM in a 
large cohort of newly diagnosed patients referred to the 
Diabetes Clinic of Verona in the last years.
SUBJECTS AND METHODS
Study population
The Verona Newly Diagnosed Type 2 Diabetes Study is an 
ongoing study on genetics, pathophysiology and clinics 
of patients with newly diagnosed T2DM.18–23As of January 
1, 2002, all patients with T2DM referred to the Diabetes 
Clinic embedded into the Division of Endocrinology, 
Diabetes and Metabolic Diseases of the University and 
Hospital Trust of Verona and whose disease was diag-
nosed in the past 6 months were offered to participate 
in this study. Recruitment was ended on December 31, 
2015 and a follow- up was then planned and is ongoing. 
All participants signed an informed consent form. The 
clinical evidence on which the diagnosis of T2DM had 
been made was reviewed at the recruitment and the diag-
nosis was confirmed according to standard criteria. The 
large majority of patients were drug- naïve (~95%) or, if 
already treated with antidiabetic drugs (~5%), under-
went a treatment washout of at least 1 week before meta-
bolic tests were performed. Exclusion criteria were age 
>75 years, non- Italian ancestry, current insulin treatment, 
presence of anti- glutamic acid decarboxylase antibodies 
and history of malignancies or any condition severely 
impairing liver and/or kidney function. In this paper, 
we report data collected from 806 patients. Not all of 
them accepted to undergo the proposed complete assess-
ment but most tests were carried out in >85% of patients. 
Cardiovascular autonomic tests were performed in 68% 
of the cohort.
Clinical data
Weight and height were measured and body mass index 
(BMI) calculated by dividing weight in kilograms by the 
square of height in meters. Waist circumference (to the 
nearest 0.5 cm) was measured with a plastic tape meter at 
the level of the umbilicus. Blood pressure was measured 
with a standard mercury manometer on the right arm 
when sitting. Hypertension was diagnosed when systolic 
blood pressure was ≥140 mm Hg and/or diastolic blood 
pressure was ≥90 mm Hg and/or antihypertensive drugs 
were used. A confirmed history of myocardial infarction, 
angina, coronary revascularization, stroke, transitory 
ischemic attack, carotid revascularization, non- traumatic 
amputation, gangrene and/or lower limb revascular-
ization was considered a valid proxy for prior clinical 
cardiovascular disease (CVD). A resting 12- lead ECG was 
performed (CardioDirect 12 unit; Metasoft 3.9 software) 
and interpreted according to Minnesota coding system.24 
In particular, ECG abnormalities were categorized as 
‘definite’, ‘probable’ or ‘possible coronary heart disease’ 
and only ‘definite’ ECG abnormalities were used for diag-
nosing myocardial ischemia. Ultrasonography scanning 
of common and internal carotid arteries was performed 
as previously described (Esaote Wall Track System, Esaote 
S.p.A., Genova, Italy) and a cut- off of 40% was used to 
define a significant arterial stenosis.22 Ultrasonography 
scanning of lower limb arteries was performed and any 
detected stenosis or moderate- to- severe reduction of 
blood flow at proximal and/or distal level was consid-
ered as a marker of peripheral artery disease. Presence 
of diabetic retinopathy (DR) was detected by indirect 
ophthalmoscopy after pupillary dilation by a single 
expert ophthalmologist. DR was categorized into back-
ground and proliferative. Distal symmetric polyneurop-
athy (DSPN) was looked for by assessing ankle reflex, 
touch sensation by Semmes- Weinstein monofilament 
and vibration perception threshold by biothesiometer. 
A dichotomous approach (yes/no) was used to catego-
rize it. Cardiovascular autonomic neuropathy (CAN) was 
searched and diagnosed as previously described.23
Laboratory testing and metabolic studies
Venous blood was drawn in the morning after an over-
night fast in all patients. Plasma glucose and serum 
creatinine and lipids were assayed by standard labora-
tory procedures. Hypercholesterolemia was arbitrarily 
defined when statins were used and/or low- density 
lipoprotein (LDL) cholesterol was above the current 
recommended target of <70 mg/dL (<1.8 mmol/L). 
Hemoglobin A1c (HbA1c) was measured with a high 
performance liquid chromatography method, standard-
ized according to IFCC. In case of discrepancy between 
the three tests (fasting plasma glucose, 2- hour plasma 
glucose, HbA1c), the one documenting diabetes (value 
above the diagnostic cut- off) was used for diagnosis 
according to standard criteria.25 Glomerular filtration 
rate (GFR) was estimated from the four- variable Modifi-
cation of Diet in Renal Disease study equation.26 Chronic 
kidney disease (CKD) was established when estimated 
glomerular filtration rate was <60 mL/min/1.73 m2. 
Urinary albumin excretion rate was measured from a 
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24- hour urine sample by an immunonephelometric 
method on at least two occasions. Microalbuminuria and 
macroalbuminuria were defined as urinary excretion of 
30–300 and >300 mg/day, respectively. Subjects under-
went a euglycemic hyperinsulinemic clamp and a 75 g 
oral glucose tolerance test (OGTT) with frequent and 
prolonged sampling (up to 4–5 hours) for assessment of 
beta- cell function which was reconstructed by mathemat-
ical modeling, as previously described.20 21
Statistical analysis
Statistical analyses were carried out with standard tech-
niques (χ2 test, multiple logistic regression analysis). 
Skewed variables were logarithmically transformed to 
improve normality before analyses were performed. Data 
are presented as median and IQR or as percentage of 
total.
RESULTS
Table 1 reports main clinical features of subjects under 
study. Two- thirds of them were males. Median age was 
60 years. Most patients were overweight or had obesity. 
Average fasting and 2- hour OGTT plasma glucose levels 
were mildly elevated and the same holds true for HbA1c. 
A number of subjects were diagnosed by OGTT or HbA1c 
rather than fasting plasma glucose. More than half of the 
subjects were treated with antihypertensive medications 
and one- fifth with statins. Blood pressure was generally 
well controlled but LDL cholesterol was above current 
target in most subjects.
Data on prior clinical CVD were available in all subjects. 
Ultrasonography of carotid artery or lower limb arteries 
in 89% and 88%, respectively. Neurological assessment 
was available in all subjects and cardiovascular autonomic 
tests in 68%. Fundus oculi was examined by ophthalmo-
scopy in 88% of subjects. Subjects undergoing insulin 
clamp and OGTT were 96% and 93%, respectively.
Table 2 summarizes the prevalence of various chronic 
complications. A prior clinical cardiovascular event was 
revealed in >10% of subjects. Another ~8% had preclin-
ical manifestations of CVD (ischemic ECG and/or 
plaques into carotid or lower limbs arteries). CKD was 
found in ~9% and albuminuria in ~13% (mostly micro-
albuminuria). DSPN was observed in ~21% and CAN 
in ~19%. Retinopathy was observed in ~5% of subjects 
(proliferative in less than one out of five).
In subjects who had a complete staging of organ/
system damage (heart, arteries, kidney, eye, nerves) 
(n=614, 76%), microvascular disease occurred in 30.8%, 
macrovascular disease in 9.3%, both in 9.1% and either 
in 49.2%. As a consequence, 50.8% had no detectable 
complications. The inclusion of CAN into this analysis 
reduced the number of subjects (n=438, 54%) but did 
not substantially change these proportions (eg, at least 
one complication was found in 50.2%).
We performed multivariate logistic regression anal-
yses in which single chronic complications were the 
dependent variables and gender, age, smoking, BMI, 
HbA1c, hypertension and hypercholesterolemia were the 
independent variables (table 3). In these analyses, CVD 
was associated with male gender, age, smoking and hyper-
tension, CKD was associated with female gender and age, 
microalbuminuria- macroalbuminuria was associated with 
male gender, smoking and HbA1c, DR was not signifi-
cantly associated with any variable in the model, DSPN 
was associated with BMI and smoking, CAN was associ-
ated with BMI, smoking and hypertension. The replace-
ment in the analyses of hypercholesterolemia with LDL 
cholesterol and hypertension with systolic blood pres-
sure did not change the results. When carotid stenosis 
or lower limb atherosclerosis were treated as dependent 
variables, the former was significantly associated with age 
and smoking, and the latter with male gender, age, hyper-
tension and hypercholesterolemia (data not shown). The 
Table 1 Main clinical features of subjects under study
Variable
Median (IQR) or 
percentage
Males (%) 68.0
Age (years) 60 (52–66)
Body mass index (kg/m2) 29.3 (26.6–32.9)





Fasting plasma glucose (mmol/L) 7.0 (6.2–7.9)
2- hour OGTT plasma glucose 
(mmol/L)
12.9 (10.4–16.0)
LDL cholesterol (mmol/L) 2.99 (2.41–3.58)
HDL cholesterol (mmol/L) 1.14 (0.96–1.34)
Triglycerides (mmol/L) 1.39 (1.03–2.0)
Statins (%) 20.5
Hypercholesterolemia (%) 96.5
Systolic blood pressure (mm Hg) 134 (120–145)
Diastolic blood pressure (mm Hg) 80 (80–90)
Antihypertensive drugs (%) 56.8
Hypertension (%) 76.7
eGFR (mL/min/1.73 m2) 81.7 (70.8–94.1)
Antiplatelet or anticoagulant drugs 
(%)
16.6
Smokers (current/prior) (%) 50.5
Insulin sensitivity (µmol/min/m2 BSA) 605 (380–874)








BSA, body surface area; eGFR, estimated glomerular filtration rate; 
HbA1c, hemoglobin A1c; HDL, high- density lipoprotein; LDL, low- 
density lipoprotein; OGTT, oral glucose tolerance test.
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inclusion of triglycerides and HDL cholesterol in the 
models yielded similar results with triglycerides being 
positively associated with CKD (OR 2.53, 95% CI 1.29 to 
4.98, p=0.007) and HDL cholesterol being negatively asso-
ciated with albuminuria (OR 0.25, 95% CI 0.09 to 0.65; 
p=0.005). The replacement of BMI with waist circumfer-
ence showed that the latter, as for BMI, was a predictor 
of CAN (OR 1.02, 95% CI 1.00 to 1.04, p=0.036; per each 
cm of waist) but not of other complications.
We have also run multivariate analyses where microvas-
cular (pooled) or macrovascular complications were the 
dependent variables and insulin sensitivity and beta- cell 
function parameters (derivative or, alternatively, propor-
tional control) were included in the models as indepen-
dent variables. In these analyses, both insulin sensitivity 
and beta- cell function (derivative control) were nega-
tively associated with macrovascular disease (table 4). No 
association of microvascular disease with these metabolic 
variables was found. This finding was confirmed when 
CAN was excluded or when single microvascular compli-
cations were treated as dependent variables (data not 
shown). When BMI was replaced by waist circumference 
and triglycerides and HDL cholesterol were included in 
the model data were substantially confirmed, although 
the association of insulin sensitivity with macrovascular 
disease lost its statistical significance. In this analysis, 
waist circumference, as for BMI, was a negative predictor 
of macrovascular disease (OR 0.98, 95% CI 0.96 to 
1.00, p=0.043; per each cm of waist) and the latter was 
not significantly associated with triglycerides or HDL 
cholesterol.
DISCUSSION
We observed that approximately 50% of subjects in this 
cohort with newly diagnosed T2DM had target organ/
system damage if the latter was searched in- depth with 
Table 2 Prevalence of chronic complications of diabetes
Complication Prevalence (%)
Overall cardiovascular disease 18.9
Prior clinical cardiovascular disease 11.2
Ischemic ECG 5.6
Carotid stenosis >40% 6.0
Lower limb stenosis (any) 6.6
Chronic kidney disease (eGFR <60 mL/
min/1.73 m2)
8.8
Albuminuria (micro or macro) 13.2
Microalbuminuria 11.9
Macroalbuminuria 1.3
Distal symmetric polyneuropathy 21.2
Cardiovascular autonomic neuropathy 18.6
Retinopathy of any type 4.9
Background retinopathy 4.2
Proliferative retinopathy 0.7
eGFR, estimated glomerular filtration rate.
Table 3 Independent predictors of single chronic complications in multivariate analyses













































































































































ORs and 95% CIs are reported. Significant p values are in bold.
BMI, body mass index; CAN, cardiovascular autonomic neuropathy; CKD, chronic kidney disease; CVD, cardiovascular disease; DR, diabetic 
retinopathy; DSPN, distal symmetric polyneuropathy; HbA1c, hemoglobin A1c; U- Alb, microalbuminuria or macroalbuminuria.
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several techniques, including ultrasonography scan-
ning of carotid and lower limb arteries, comprehensive 
neurological evaluation and ophthalmoscopy. Focusing 
on microvascular complications (eye, kidney, nerves), 
test abnormalities compatible with neuropathy were 
more common than those documenting retinopathy or 
nephropathy. This observation is noteworthy as neurop-
athy is often a neglected microvascular complication of 
diabetes because the eye and the kidney generally receive 
more attention than nerves. Overall, as many as 40% of 
subjects had microvascular disease, with a proportion 
twofold higher than macrovascular disease. Noteworthy, 
as many as 10% had both microvascular and macrovas-
cular damage and as many as ~50% had either.
We have observed that gender, age, BMI, smoking, 
HbA1c and hypertension were variably associated with 
specific microvascular complications and gender, age, 
smoking and hypertension were associated with macro-
vascular complications. Interestingly, male gender was 
associated with CVD whereas female gender was asso-
ciated with CKD. A classic risk factor such as hyper-
cholesterolemia was not associated with macrovascular 
complications and hypertension was not associated with 
CKD. The cross- sectional setting of the study is the likely 
explanation. Yet, almost all subjects were on statins or 
had cholesterol levels above the cut- off of 70 mg/dL and 
the majority of hypertensive subjects were on treatment.
Insulin sensitivity and insulin secretion were negatively 
associated with macrovascular complications. In previous 
longitudinal studies, we found that insulin resistance was 
a predictor of CVD in T2DM and in the general popula-
tion.27 28 In a study conducted several years ago in the UK, 
Roy Chowdhury et al29 observed an association between 
impaired insulin secretion and retinopathy but no 
association of this complication with insulin sensitivity. 
However, they used different and surrogate methods (eg, 
Homeostasis Model Assessment) to assess insulin secre-
tion and sensitivity. Martinell et al11 observed an inverse 
association between insulin secretion and retinopathy 
and no association with insulin resistance. However, they 
have used surrogate methods to assess these metabolic 
functions. We were unable to observed any association of 
insulin secretion with microvascular disease.
In this study, we explored virtually all classic sites 
of chronic complications (heart, arteries, eye, kidney, 
nerves) and this is at variance with most previous 
studies, some of which are also quite dated. In these 
studies, conducted in the last 40 years in large cohorts 
of patients with newly diagnosed T2DM recruited in 
Western countries, the prevalence of complications was 
quite variable, most likely for substantial differences in 
the methods of their detection.2–16 Prevalence of reti-
nopathy ranged from 1%4 to 21%.2 Prevalence of DSPN 
ranged from 3%13 to 42%.16 Prevalence of microalbu-
minuria/macroalbuminuria ranged from 7%3 to 20%.10 
CKD was observed in 3%2 13 up to 21%.9 In these studies, 
prior cardiovascular events were often presented sepa-
rately: myocardial infarction ranged from 5%13 to 
11%,12 stroke ranged from 2%10 to 5%,8 peripheral 
vascular disease ranged from 2%4 14 to 40%.8 In none 
of these studies, carotid or lower limb ultrasonography 
were used to detect plaques and only one of them 
explored CAN, finding a prevalence of 4%.16 Therefore, 
we feel that our study is more comprehensive than those 
previous studies.
Multivariate analyses were run only in few of the above 
referenced studies. Looker et al5 found associations of 
retinopathy with male gender, HbA1c, BMI and blood 
pressure. An association of retinopathy with male gender, 
HbA1c and blood pressure was observed also by Kostev 
and Rathmann.6 Kostev et al8 have reported that DSPN 
was associated with male gender and age. Interestingly, 
we found an association between smoking and neurop-
athy (both DSPN and CAN). This finding is consistent 
with recent data from others30 31 and could be attributed 
to the damage exerted by smoking on vasa nervorum as 
well as its direct detrimental effects on nerve structure 
and function. The latter includes an increased oxida-
tive stress, with reactive oxygen species and Advanced 
Glycosilation End- Products as mediators, leading to 
mitochondrial dysfunction, inflammation, DNA damage 
and apoptosis.32 33 The lack of significant associations of 
HbA1c with some of the complications (eg, neuropathy 
Table 4 Independent predictors of macrovascular and 
pooled microvascular complications in multivariate analyses 




2.15 (1.26 to 3.68)
p=0.005




1.07 (1.04 to 1.10)
p<0.001




0.94 (0.89 to 0.99)
p=0.012




2.38 (1.52 to 3.73)
p<0.001




1.17 (0.28 to 4.79)
p=0.830




2.93 (1.57 to 5.48)
p=0.001




1.17 (0.40 to 3.48)
p=0.775




0.70 (0.50 to 0.99)
p=0.043
1.01 (0.69 to 1.46)
p=0.974
Beta- cell function 
(derivative control)
(per log unit)
0.92 (0.86 to 0.99)
p=0.023
1.03 (0.95 to 1.11)
p=0.474
Macrovascular=prior CVD and/or ischemic ECG and/or carotid 
stenosis and/or lower limb stenosis. Microvascular=CKD and/
or microalbuminuria- macroalbuminuria and/or DR and/or DSPN 
and/or CAN. ORs and 95% CIs are reported. Significant p 
values are in bold.
BMI, body mass index; CAN, cardiovascular autonomic 
neuropathy; CKD, chronic kidney disease; CVD, cardiovascular 
disease; DR, diabetic retinopathy; DSPN, distal symmetric 
polyneuropathy; HbA1c, hemoglobin A1c.
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or retinopathy) is reasonably due to the cross- sectional 
design of the study.
As far as we know, this is the only study exploring in 
the same cohort all major complications of diabetes and 
relating them to classic risk factors and to major patho-
genic determinants of T2DM (ie, insulin resistance and 
beta- cell dysfunction). We feel that our data are important 
as they point out to what extent the diabetes milieu can 
deteriorate health status of subjects before diagnosis 
even in the presence of mild- to- moderate hyperglycemia 
and how often chronic complications might be detected 
at time of diabetes diagnosis if they are carefully and 
comprehensively searched. This happens despite the 
increased awareness for diabetes occurred in the last 
20–30 years. Yet, a role of insulin resistance in macro-
vascular disease emerged independently of classic risk 
factors, thus consolidating previous findings in subjects 
with and without diabetes.27 29
Strengths of the study are: large number of subjects; no 
selection of patients (only those older than 75 years were 
not examined); exclusion of patients with Latent Auto-
immune Diabetes of Adults; lack of any interference by 
antihyperglycemic drugs; assessment of all major organs/
systems suffering from chronic hyperglycemia, including 
autonomic nervous system; investigation of carotid and 
lower limb arteries and not solely of prior CVD clinical 
events; measurement of insulin sensitivity and insulin 
secretion with state- of- the- art techniques.
Limits of the study are: inclusion of Caucasian subjects 
only; lack of investigation of CHD with dynamic tech-
niques (eg, stress ECG or stress echocardiography).
In conclusion, despite a generally earlier diagnosis of 
T2DM occurring in the last two decades as compared 
with previous decades for an increased awareness of the 
disease, as many as ~50% of newly diagnosed patients 
have clinical or preclinical manifestations of microvas-
cular and/or macrovascular disease. Our findings might 
promote an additional effort to further anticipate T2DM 
diagnosis by tracing undetected cases. Yet, our study 
might translate into a stronger commitment for staging 
organ/system damage in T2DM as soon as the diagnosis 
is established.
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